Study Links GLP‑1 Drugs to Lower Cancer Risk in Women

A large observational study published in JAMA Oncology by researchers at Indiana University and the University of Florida analyzed electronic health records from 2014–2024 for 86,632 adults eligible for anti‑obesity medications and found GLP‑1 receptor agonist use was associated with a significantly lower overall cancer risk—notably endometrial, ovarian and meningioma cancers—while also noting an association with higher kidney‑cancer incidence; authors call for longer‑term follow‑up to clarify mechanisms and clinical implications.